Reversible Fanconi syndrome in a pediatric patient on deferasirox

Michelle N. Rheault, Heather Bechtel, Joseph P. Neglia, Clifford E. Kashtan

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Deferasirox (Exjade®, Novartis) is a widely used oral iron chelator for the treatment of patients with iron overload due to chronic transfusion therapy for diseases such as β-thalassemia and sickle cell disease. Renal side effects of deferasirox are common and include non-progressive increases in serum creatinine, however, the effect of deferasirox on proximal tubule function is unclear. We report one pediatric patient with reversible Fanconi syndrome associated with long-term deferasirox therapy and one patient with mild proximal tubular dysfunction. Kidney and proximal tubular function should be periodically monitored in patients receiving deferasirox throughout their course of therapy.

Original languageEnglish (US)
Pages (from-to)674-676
Number of pages3
JournalPediatric Blood and Cancer
Issue number4
StatePublished - Apr 2011


  • Iron chelation
  • Iron overload
  • Kidney
  • Proximal tubular dysfunction
  • β-thalassemia


Dive into the research topics of 'Reversible Fanconi syndrome in a pediatric patient on deferasirox'. Together they form a unique fingerprint.

Cite this